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Commentary
Ethical Considerations for Acupuncture and Chinese Herbal
Medicine Clinical Trials: A Cross-cultural Perspective*
Christopher Zaslawski
College of Traditional Chinese Medicine, Department of Medical and Molecular Biosciences, Faculty of Science,
University of Technology, Sydney, Australia
Many ethical concerns revolve around the four basic principles of research: merit and integrity,
respect for human beings, weighting of risk–benefit and justice. These principles form the basis
for any discussion concerning human research ethics and are applicable to all areas of research
including acupuncture and Chinese herbal medicine. World Health Organisation document,
Guidelines for Clinical Research on Acupuncture, states that ‘consideration should be given to
the different value systems that are involved in human rights such as social, cultural and
historical issues’ and that ‘further studies should be conducted in relation to ethical issues
involved in clinical research on acupuncture’. In addition to outlining the four basic principles,
this paper will also examine the effect of Asian culture on Western human research ethics and
how this may impact upon issues such as informed consent and weighting of risk–benefit.
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Introduction
Over the past three decades there have been many
developments concerning acupuncture and Chinese med-
icine (CM) research methodology (1). In addition, there
has been increasing interest, especially in Western
countries, on the consideration of ethics on research
design (2). The World Health Organisation document,
Guidelines for Clinical Research on Acupuncture (3), states
that ‘consideration should be given to the different value
systems that are involved in human rights such as social,
cultural and historical issues’ and that ‘further studies
should be conducted in relation to ethical issues involved
in clinical research on acupuncture’.
Most Western and an increasing number of Asian
countries now require that research projects involving
humans have independent ethical review prior to initiating
research. A committee, often comprising medical and
non-medical persons, usually conducts these reviews. The
reviews are undertaken to ensure the protection of the
welfare and rights of research participants as well as
the facilitation of research that will benefit society and
humankind. In the United States, these committees are
called Independent Review Boards, while in the United
Kingdom they are termed Research Ethics Committees and
in Australia, Human Research Ethics Committees. Indeed,
many funding bodies require that such a committee
approve proposals before releasing funding for the
research. In addition, many ethics committees require that
research conducted overseas under the direction of local
institution comply with the local ethical requirements. The
Declaration of Helsinki, an international set of guidelines
for ethical research adopted by the World Medical
Association,isclearinenunciatingtheneedforacommittee
to review research proposals involving humans (4).
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This protocol should be submitted for consider-
ation, comment, guidance and where appropriate
approval to a specially appointed ethical review
committee, which must be independent of the
investigator, the sponsor or any kind of undue
influence.
Paragraph 9 reiterates
Research Investigators should be aware of the
ethical, legal and regulatory requirements for
research on human subjects in their own country
as well as applicable international requirements.
Many ethical concerns revolve around the four basic
principles of research merit and integrity, respect for
human beings, weighting of risk–benefit and justice.
These principles form the basis for any discussion
concerning human research ethics and are applicable to
all approaches (quantitative or qualitative) and types
(clinical or non-clinical) of research including CM.
Research Merit and Integrity
Establishing research merit and integrity is necessary for
the ethical involvement of human participants. The trial
design should use recognized principles of research with
tangible, clinically relevant measurable outcomes. The
unique characteristics of the clinic practice of CM such as
pattern differentiation and individualization of treatment
make it difficult to translate into accepted research
models. This can pose difficulties for the ethics committee
if they are unfamiliar with the principles of CM, as well
as for the researchers who may submit proposals with
novel design innovations to accommodate such clinical
practice characteristics (5).
Defining the research question and engaging in ongoing
dialogue with the ethics committee are important
strategies if there is to be a meaningful and successful
relationship. Both the researchers and the ethics commit-
tee will have to learn from one another if they are to
fulfill their obligations (6). This can be a new experience
for CM practitioners who may be undertaking research
for the first time, are unaccustomed to operating within a
Western research paradigm and who may find the process
of seeking ethics approval intimidating.
An important issue relating to integrity involves the
existence of equipoise. Equipoise has been defined as
‘a state of genuine uncertainty on the part of the clinical
investigator regarding the comparative therapeutic merits
of each arm in a trial’ (7). Small preliminary pilot studies
or effectiveness studies can be very informative in estab-
lishing equipoise. Fønnebø and colleagues (8) have
recently suggested a phased research activity sequence
that included safety status and randomized controlled
pragmatic studies prior to commencing efficacy-focused
research. Preliminary pilot studies have also been under-
taken in the context of efficacy studies. A recent example
is the series of knee osteoarthritis studies conducted by
Berman and colleagues (9–11). Failure to have conducted
a preliminary study that showed possible benefit (equi-
poise) may not only waste public grant monies but also
the participant’s time and efforts. Research therefore
should be staged to justify the efficient use of public
monies and participant’s contribution.
In order to be ethical, research must be conducted
or supervised by persons or teams with the experience,
qualifications and competence appropriate to the research.
An important consideration for ‘hands on’ type research
such as acupuncture is the skill and competence of the
acupuncturist administering the interventions. Unfortu-
nately, some studies fail to use qualified, competent
practitioners. Furthermore, the acupuncturist should
have experience in the treatment of the condition being
studied. When reporting the study, the qualification, the
length of training and clinical experience of the acupunc-
turist should be stated.
In addition, the results of research and the methods
used should be published in ways that permit scrutiny.
This means full reporting of all stages of the research.
A number of international standards exist that gives
guidance and provide checklists for improving study
design. A good example is the Consolidated Standards
of Reporting Trials (CONSORT) statement that lists
22 items for improving the quality of parallel group
randomized trials (12). More recently, guidelines have
been developed for reporting acupuncture and Chinese
herbal medicine research (13–15).
Dissemination of research results is another often
overlooked ethical issue. Clinical research that has a
negative outcome is frequently not submitted for
publication. In addition, journal editors may have a
bias against publication of a negative outcome trial.
Reporting of negative trials should be encouraged.
Failure to do so has been blamed for distorting the
medical literature. The Declaration of Helsinki (para-
graph 27) (4) is explicit in this regard, stating that
Both authors and publishers have ethical obliga-
tions. In publication of the results of research,
the investigators are obliged to preserve the
accuracy of the results. Negative as well as
positive results should be published or otherwise
publicly available.
The open access BMC (Biomed Central) Journal of
Negative Results in BioMedicine represents a very novel
approach to dealing with editorial bias (16).
Finally, the acknowledgement of sponsorship and
conflicts of interest should be reported as conflicts
involving personal, professional or financial situations
can actually or potentially affect judgments. Of all
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journals, only two require such a declaration (17).
Respect for Human Beings
The second issue of respect for human beings requires
that participants choose whether or not to become
involved in a research study. Central to this concept is
the participant’s informed consent.
General requirements for consent involve:
 Voluntary participation that is based on sufficient
information and understanding of the purpose,
methods, demands, risks, inconvenience, discomforts
and possible outcomes of the research
 That the participant is not subject to coercion or to
inducement and that the participation is clearly
established such as a signed form, return of a
survey or a recorded audio agreement.
In many Western countries, informed consent is
obtained by using a document that is signed by both
the participant and the researcher. However, a recent
review of acupuncture trials found that of the 47 sham-
controlled acupuncture trials reported, only 10 studies
included information on how participants were informed
(18). They also found that information strategies varied
considerably and were often not fully explicit, informing
participants that a sham intervention is involved.
The need to explicitly inform study participants can
be especially problematic for acupuncture research. Acu-
puncture needling, as well as being difficult to mimic
visually, also elicits distinct physical sensations. Control
interventions such as inactive TENS or a placebo
medication are likely to produce a different psychological
response compared with acupuncture (19). In addition,
sham procedures such as the recently devised non-
invasive retractable ‘stage dagger’ needle may make it
increasing difficult to deceive experienced acupuncture
participants over a period of time (20). If participants are
alerted to the possibility of receiving a sham or a placebo
treatment at the informed consent stage, it may make it
difficult to reliably blind the participants to the control
intervention. This raises the question of whether partially
informed consent can be ethical. Miller and Kaptchuk
(21) argue strongly that ‘accurate disclosure, consistent
with informed consent, should take precedent over
deceptive disclosure for the sake of maximizing scientific
validity, especially in the absence of rigorous data
showing that accurate disclosure undermines satisfactory
blinding of participants’.
A recent study evaluated the ethical concerns over their
use of partial consent in a randomized non-pharmacolo-
gical study that used a placebo intervention (22).
They reported that on completion of the study after the
subjects had been informed of the intervention status,
both groups agreed with the informed consent procedure.
They further argue that partial consent may be
justified if:
 the target illness does not demand urgent medical
attention;
 the treatment is low risk;
 the risks have been adequately assessed and can be
satisfactorily managed;
 the merit of the research far outweighs the risk to the
participant;
 there is no known treatment for the target illness;
 the internal validity of the study is threatened
(failure to blind);
 that participants are informed explicitly (in the
consent form) that they would not receive any
information on the specific goals of the
interventions;
 participants are told that the specifics of the
interventions will be given at the completion of
the study.
The case for participant deception and partial consent
needs further discussion and may be possible under
specific conditions.
Another ethical concern often voiced is that rando-
mized controlled trials (RCTs) ignore participant pre-
ference. This is particularly the case where CM has
widespread accepted use. For example in China or
Korea, acupuncture and herbal medicine are accepted
as valid therapies and participants are reluctant to enter a
randomized trial for fear of not receiving their treatment
choice (23). A number of modified RCT designs that
account for participant preferences have been suggested
and tried in the West (24). These include the Baskerville
design (Fig. 1) and the comprehensive cohort design
(Fig. 2). The Baskerville design allows participants to
choose whether they remain with the group they have
been randomized to, cross over into the other group or
withdraw from the trial. The comprehensive cohort
design allows participants to chose, prior to randomiza-
tion, whether they wish to be randomized. Those that
choose not to be randomized are free to further decide
whether they enter the treatment or control group. Those
that agree to randomization are then randomized to
either the treatment or the control group. These two
designs, however, could be used only when participants
are to be informed of their group allocation (e.g. wait list,
active control). They could not be used when a sham or
placebo control is used. In addition, it may be difficult to
recruit sufficient numbers for the control group, with the
distinct possibility that most participants would opt for
the treatment group. A second possible problem is the
unknown potential of allocation bias as a confounder
when interpreting results from such trials. Interestingly,
a recent review of 32 patient preference studies found
little evidence that trials that use such designs
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randomized trials (25). Further research needs to be
undertaken before widescale use of patient prefer-
ence trials are undertaken to ensure that they do not
introduce bias.
Cross-cultural Research
As globalization increases, the potential for international
research collaboration will intensify. The acupuncture
breech birth study conducted by Italian researchers using
Chinese resources is a recent example (26). China, with its
rich resources, human capital and its complex cultural
interplay is a mixed blessing. China’s potential is offset
by her vulnerability with ‘the rush to claim patents for
and intellectual property rights to the resulting products
and benefits fuels competition rather than scientific
detachment and proper attention to the needs and
claims of vulnerable groups’ (27). To make it even
more complex, the ongoing situation involves evaluating
a process rather than its results. Chinese and Asian
bioethicists continue to struggle to define, reframe and
develop bioethics that is in harmony with China’s
cultural and moral inheritance. Drawing on Confucian,
Buddhist and Taoist perspectives, many Chinese bioethi-
cists argue that China’s contemporary situation cannot be
Figure 1. The Baskerville modified RCT design [adapted from Ernst (24)].
Figure 2. The comprehensive cohort design [adapted from Ernst (24)].
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from very different cultural forces (28–30). Furthermore,
the transition from a planned economy to a market
economy will lead to further ethical reconsideration (31).
With this perspective in mind, a number of problems
arise when applying Western research ethics in an Asian
culture.
One such difficulty concerns the cultural differences
associated with obtaining informed consent (32). From
the Western ethical perspective, the individual is seen
as an autonomous agent with the ability to freely choose
without consideration of others. Confucian ethics, on
the other hand, perceive the individual as being situated
within a complex familial (filial piety) and societal
network, where the decision to become involved in a
research study may often be influenced by relationships
and responsibilities (33). It may be necessary to obtain
consent from family members as well as the participant.
This may especially be the case where the participant
is a sick patient. Occasionally, the participant may not
want to consent and family members agree or the patient
may give consent but the family will not. Disputes may
arise when the opinion of family members are neglected.
Researchers may need to obtain a mutual agreement
between participants and family members.
Furthermore, written consent may be difficult to obtain
and it may be culturally insensitive to insist the
participant sign a consent form. In Chinese culture, the
signing of a consent form would be seen similar to
signing oneself into indenture and many participants
would rather orally consent than sign their name on
paper (34). In this case, verbal consent can be obtained
and formally documented or recorded.
If the consent cannot be obtained in writing, the
non-written consent must be formally documen-
ted and witnessed.
The Helsinki Declaration (paragraph 22) (4)
Another potential issue is the use of placebo-controlled
studies. Historically, the value system of Chinese medical
ethics can be traced back to the Confucian precept that
medicine is a humane art. Medicine is not only a means
to help people during illness but a moral obligation to
love people and relieve their suffering through personal
caring and medical treatment (35). Use of a placebo is
seen as depriving or cheating a patient of a valuable
treatment and this has been reflected in the large number
of uncontrolled cohort studies and single case reports in
the Chinese medical literature and translated publications
in the West (23). In the current evidence-based climate,
such research designs are perceived to have little scientific
merit and more appropriate designs such as outcome
research may be more suitable.
Further exploration of cross-cultural ethics is required.
Researchers need to be aware that the ethical values by
which research is designed and conducted continue to
respect the variety of opinion associated with different
cultural perspectives.
Weighting of Risk–Benefit
The declaration of risks and benefits is an integral aspect
of informed consent. Participants should be aware of
the range and incidence of adverse events associated
with their involvement in a research study. Again, the
Declaration of Helsinki is explicit in this regard
Every medical research project involving human
subjects should be preceded by careful assess-
ment of predictable risks and burdens in
comparison with foreseeable benefits to the
subject or to others.
The Helsinki Declaration (paragraph 16) (4)
A number of recent reports have shown acupuncture to
have a very low rate of adverse events associated with its
practice. White (36), in reviewing the literature, reported
on the outcomes of more than a million acupuncture
treatments. He found that the risk of a serious adverse
event was estimated to be 0.05/10000 treatments and
0.55/10000 individual patients. Similarly published
reports have identified a number of side effects attributed
to Chinese herbal medicine including stomach upset, skin
rash and bleeding gums. Whilst Chinese herbs have been
in common usage for at least 2000 years, the safety and
the incidence of adverse events and their frequency is not
well established (37). It is common for an ethics
committee to require that herbal researchers report the
known toxicological, pharmacological and adverse event
data within their application in order to evaluate the
risk–benefit ratio. While many of these reactions may be
of minor concern, they should nevertheless be mentioned
within the consent form (38).
In addition to informing participants of the risks,
adverse events should also be monitored during the
study. Participants should be asked at the completion of
each intervention session, and prior to the following
session, whether they experienced any undue reactions
or uncomfortable sensations. All suspected adverse events
should be reported and evaluated according to the
likelihood that the acupuncture or herbal medicine
contributed in eliciting them.
Placebo Controls—An Ethical Alternative?
One of the most controversial issues in research involves
selection of the control intervention (39,40). While the
research question may be important in deciding what
type of control condition is used, there are ethical
concerns if a wait list or placebo control is employed.
Both of these control conditions involve the delay or
eCAM 2010;7(3) 299denial of standard medical care. In this day and age, very
few diseases or illnesses do not receive at least partial
benefit from standard medical care; therefore, the use of
a placebo or a no-treatment control could be considered
harmful and hence unethical. The 2000 Declaration of
Helsinki is clear in enunciating this perspective (para-
graph 29) (4):
The benefits, risks, burdens and effectiveness of
a new method should be tested against those
of the best current prophylactic, diagnostic, and
therapeutic methods. This does not exclude the
use of placebo, or no treatment, in studies where
no proven prophylactic, diagnostic or therapeutic
method exists.
Following the publication of the fifth revision of the
Helsinki Declaration in 2000 (4), debate intensified
concerning the use of placebo control groups especially
when effective treatments are available. Opponents of the
use of a placebo in a clinical trial argued that:
‘every patient-including those ofa control group,if
any- should be assured of the best proven
diagnostic and therapeutic method.’ This state-
ment effectively proscribes the use of a placebo as
control when a ‘proven’ therapeutic method exists.
The Helsinki declaration also directs that a study
that violates its precepts should not be accepted for
publication...there is no straightforward way to
estimate how many trials are undertaken that
involve the unethical use of placebos.
Rothman and Michels (41)
The ensuing debate resulted in the World Medical
Association in 2002 (4) publishing a note of clarification
on paragraph 29.
The WMA hereby reaffirms its position that
extreme care must be taken in making use of a
placebo-controlled trial and that in general this
methodology should only be used in the absence
of existing proven therapy. However, a placebo-
controlled trial may be ethically acceptable, even
if proven therapy is available, under the follow-
ing circumstances:
– Where for compelling and scientifically sound
methodological reasons its use is necessary to
determine the efficacy or safety of a prophylactic,
diagnostic or therapeutic method; or
– Where a prophylactic, diagnostic or therapeutic
method is being investigated for a minor condition
and the patients who receive placebo will not be
subject to any additional risk of serious or
irreversible harm.
Researchers are obliged to consider if the risks and
burdens to the participant, from delaying or denying a
proven therapeutic treatment, outweigh the research
objectives. The Declaration of Helsinki is again quite
clear in expressing this view (paragraphs 16 and 17) [4].
Every medical research project involving human
subjects should be preceded by careful assess-
ment of predictable risks and burdens in
comparison with foreseeable benefits to the
subject or to others...
Physicians should abstain from engaging in
research projects involving human subjects unless
they are confident that the risks involved have
been adequately assessed and can be satisfacto-
rily managed. Physicians should cease any
investigation if the risks are found to outweigh
the potential benefits
If the disease to be treated in the trial were chronic and
stable, and the withholding of a proven therapeutic
treatment constitutes a low risk to the participant, then
the ethical concerns of using a placebo would be minimal.
One strategy to ensure the participants were not denied
effective treatment, especially if the acupuncture or herbal
medicine was shown to be beneficial, is to offer
the participant treatment at the completion of the trial.
This strategy could be explicitly stated in the study
protocol. The 2004 note of clarification to paragraph 30
(4) states that:
The WMA hereby reaffirms its position that it is
necessary during the study planning process to
identify post-trial access by study participants to
prophylactic, diagnostic and therapeutic proce-
dures identified as beneficial in the study or
access to other appropriate care. Post trial access
arrangements or other care must be described in
the study protocol so the ethical review commit-
tee may consider such arrangements during its
review.
If on the other hand, the disease was progressing quickly
or had serious consequences if the proven therapeutic
treatment was withheld, then the only ethical option
would be to ensure the use of the proven therapeutic
treatment in all arms of the trial. In this case, the
acupuncture or herbal medicine treatment would be an
adjunct to the standard treatment. The consideration of
beneficence and non-maleficence remain central to the
issue and the delay or withholding of a proven
therapeutic treatment has to be balanced against the
impact upon the participant’s disease or state of health.
In summary, the consideration of ethics in the design
and conduct of acupuncture and Chinese herbal medicine
clinical trials is fundamental to good research. Ethical
consideration of research involves the protection of the
welfare and rights of the participants in the research.
300 Acupuncture and Chinese herbal medicine clinical trialsIt also entails the development of rigorous research that
will be of benefit to humankind. It is hoped that this
paper will generate more questions on the role of ethics
in CM clinical trial design.
References
1. Birch S. Clinical research on acupuncture: part 2. Controlled clinical
trials, an overview of their methods. J Alternat Complement Med
2004;10:481–98.
2. Miller FG, Emanuel EJ, Rosenstein DL, Strauss SE. Ethical issues
concerning research in complementary and alternative medicine.
J Am Med Assoc 2004;291:599–604.
3. World Health Organization Regional Office for the Western Pacific.
Guidelines for Clinical Research on Acupuncture. World Health
Organization, Manila: Philippines, 1995.
4. World Medical Association Declaration of Helsinki. Available at
www.wma.net/e/policy/b3.htm. Accessed 22 March 2008.
5. Schnyer RN, Wayne PM, Kaptchuk TJ, Cheng XM, Zhang ZZ,
Stason WB. Standardization of individualized treatments in a
randomized controlled trial of acupuncture for stroke rehabilitation.
J Altern Complement Med 2006;12:106–9.
6. Zaslawski CJ, Davis S. The ethics of complementary and alternative
medicine research: a case study of traditional Chinese medicine at
the University of Technology, Sydney. Monash Bioethics Rev
2005;24:52–61.
7. Freedman B. Equipoise and the ethics of clinical research. New Engl
JM e d1987;317:141–5.
8. Fønnebø V, Grimsgaar S, Walach H, Ritenbaugh C, Norheim AJ,
MacPherson H, et al. Researching complementary and alternative
treatments – the gatekeepers are not at home. BMC Med Res
Methodol 2007;7:7.
9. Berman B, Lao L-X, Greene M, Anderson RW, Wong RH,
Langenberg P, et al. Efficacy of traditional Chinese acupuncture in
the treatment of symptomatic knee osteoarthritis: a pilot study.
Osteoarthritis Cartilage 1995;3:139–42.
10. Berman BM, Singh BB, Langenberg P, Li H, Hadhazy V, Bareta J,
et al. A randomised trial of acupuncture as an adjunctive therapy in
osteoarthritis of the knee. Rheumatology 1999;38:346–54.
11. Berman BM, Lao L, Langenberg P, Lee WL, Gilpin AMK,
Hochberg MC. Effectiveness of acupuncture as adjunctive
therapy in osteoarthritis of the knee. Ann Intern Med 2004;
141:901–10.
12. Moher D, Schulz KF, Altman D. The CONSORT Statement:
revised recommendations for improving the quality of reports of
parallel-group randomized trials 2001. Explore (NY) 2005;1:40–5.
13. MacPherson H, White A, Cummings M, Jobst KA, Niemtzow RC.
Standards for reporting interventions in controlled trials
of acupuncture: the STRICTA recommendations. J Altern
Complement Med 2002;8:85–9.
14. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C.
Reporting randomized, controlled trials of herbal interventions: an
elaborated CONSORT statement. Ann Intern Med 2006;144:364–7.
15. Bian ZX, Moher D, Dagenais S, Li YP, Wu TX, Liu L, et al.
Improving the quality of randomized controlled trials in Chinese
herbal medicine, part IV: applying a revised CONSORT checklist to
measure reporting quality. J Chinese Integr Med 2006;4:233–42.
16. Journal of Negative Results in Biomedicine. Available at http://
www.jnrbm.com. Accessed 22 March 2008.
17. Ernst E. Research ethics in CAM. Focus Altern Complement Ther
2005;10:171–6.
18. Linde K, Dincer F. How informed is consent in sham-
controlled trials of acupuncture? J Altern Complement Med
2004;10:379–85.
19. Kaptchuk TJ, Stason WB, Davis RB, Legedza ATR, Schneyer RN,
Kerr CE, et al. Sham device v inert pill: a randomised controlled
trial of two placebo treatments. Br Med J 2006;332:391–7.
20. Tsukayama H, Yamashita H, Kimura T, Otsuki K. Factors
which Influence the Applicability of Sham Needle in Acupuncture
Trials: Two Randomised, Single Blind, Cross-Over Trials
with Acupuncture-Experienced Subjects. 6th World Federation of
Acupuncture-Moxibustion Societies Conference, Gold Coast,
Australia, 2004.
21. Miller FG, Kaptchuk TJ. Acupuncture trials and informed consent.
J Med Ethics 2007;33:43–4.
22. Spigt MG, Knipschild PG, van Schayck CP, Knottnerus JA.
The validity and ethics of giving placebo in a randomised
non-pharmacological trial was evaluated. J Clin Epidemiol
2005;58:350–6.
23. Xie Z. Clinical trials in traditional Chinese medicine. J Clin Ethics
2004;15:51–4.
24. Ernst E. RCTs for CAM. Focus Altern Complement Ther
2005;10:9–12.
25. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M,
et al. Impact of participant and physician intervention preferences
on randomized trials. J Am Med Assoc 2005;293:1089–99.
26. Cardini F, Weixin H. Moxibustion for correction of breech
presentation: a randomized controlled trial. J Am Med Assoc
1998;280:1580–4.
27. Doring O. Chinese researchers promote biomedical regulations:
what are the motives of the biopolitical dawn in China and where
are they heading? Kennedy Inst Ethics J 2004;14:39–46.
28. Li Y-Z. Epistemological and methodological problems in studies of
traditional Chinese ethical scholarship. New Literary Hist
1995;26:519–36.
29. Fan R. Reconstructionist Confucianism and health care: an Asian
moral account of health care resource allocation. J Med Philos
2002;27:673–82.
30. Du Z-Z. On the development of teachers of medical ethics in China.
The Hastings Centre Report 2000;30:S37–40.
31. Fan R-P. Towards a Confucian virtue ethics bioethics: reframing
Chinese medical ethics in a market economy. Theor Med Bioethics
2006;27:541–66.
32. Dawson L, Kass NE. Views of US researchers about informed
consent in international collaborative research. Social Sci Med
2005;61:1211–22.
33. Li B-F. Informed consent in research involving human subjects.
J Clin Ethics 2004;15:35–7.
34. Yuan L. Clinical trials in China: protection of subjects’ rights and
interests. J Clin Ethics 2004;15:30–4.
35. Zhang D-Q, Cheng Z-F. Medicine is a humane art. The basic
principles of professional ethics in Chinese medicine. The Hastings
Centre Report 2000;30:S8–12.
36. White A. A cumulative review of the range and incidence of
significant adverse events associated with acupuncture. Acupuncture
Med 2004;22:122–33.
37. Barnes J. Quality, efficacy and safety of complementary medicines:
fashions, facts and the future. Part II: efficacy and safety. Br J Clin
Pharmacol 2003;55:331–40.
38. Ioannnidis JPA, Evans SJW, Gotzsche PC, et al. Better reporting of
harms in randomized trials: an extension of the CONSORT
statement. Ann Intern Med 2004;141:781–8.
39. Vickers AJ, de Craen AJM. Why use placebos in clinical trials?
A narrative review of the methodological literature. J Clin Epidemiol
2000;53:157–61.
40. Cleophas TJM. Clinical trials: specific problems associated with the
use of a placebo-control group. J Mol Med 1995;73:421–4.
41. Rothman KJ, Michels KB. The continuing unethical use of placebo
controls. New Engl J Med 1994;331:394–8.
Received October 25, 2007; accepted May 27, 2008
eCAM 2010;7(3) 301